CN1388758A - 抗结核病药物的新颖的药学组合物及其制备方法 - Google Patents

抗结核病药物的新颖的药学组合物及其制备方法 Download PDF

Info

Publication number
CN1388758A
CN1388758A CN01802338A CN01802338A CN1388758A CN 1388758 A CN1388758 A CN 1388758A CN 01802338 A CN01802338 A CN 01802338A CN 01802338 A CN01802338 A CN 01802338A CN 1388758 A CN1388758 A CN 1388758A
Authority
CN
China
Prior art keywords
rifampicin
isoniazid
compositions
tablets
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01802338A
Other languages
English (en)
Chinese (zh)
Inventor
A·辛格
R·贾殷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panacea Biotec Ltd
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CN1388758A publication Critical patent/CN1388758A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN01802338A 2000-08-09 2001-04-10 抗结核病药物的新颖的药学组合物及其制备方法 Pending CN1388758A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN720DE2000 2000-08-09
IN720/DEL/2000 2000-08-09

Publications (1)

Publication Number Publication Date
CN1388758A true CN1388758A (zh) 2003-01-01

Family

ID=11097078

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01802338A Pending CN1388758A (zh) 2000-08-09 2001-04-10 抗结核病药物的新颖的药学组合物及其制备方法

Country Status (22)

Country Link
US (1) US7195769B2 (enExample)
EP (1) EP1307199A2 (enExample)
JP (2) JP4098620B2 (enExample)
KR (1) KR100620404B1 (enExample)
CN (1) CN1388758A (enExample)
AU (1) AU778389C (enExample)
BG (1) BG65848B1 (enExample)
BR (1) BR0107147A (enExample)
CA (1) CA2386725A1 (enExample)
CZ (1) CZ20021319A3 (enExample)
HU (1) HUP0203451A3 (enExample)
IL (2) IL149030A0 (enExample)
MX (1) MXPA02003596A (enExample)
NO (1) NO322503B1 (enExample)
NZ (1) NZ518216A (enExample)
PL (1) PL355844A1 (enExample)
RU (1) RU2240795C9 (enExample)
TR (1) TR200200966T1 (enExample)
UA (1) UA74164C2 (enExample)
WO (1) WO2002011728A2 (enExample)
YU (1) YU26102A (enExample)
ZA (1) ZA200202637B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857220B (zh) * 2006-04-04 2010-10-06 济南康泉医药科技有限公司 一种抗结核病药物缓释剂
CN102228439A (zh) * 2011-06-21 2011-11-02 中国人民解放军第三○九医院 可注射利福霉素类抗生素凝胶微球及其制备方法
CN102325526A (zh) * 2008-12-19 2012-01-18 Aai医药服务公司 延长释放的药物制剂
CN102552204A (zh) * 2011-12-30 2012-07-11 沈阳药科大学 复方抗结核包芯片及制备方法
CN102579447A (zh) * 2011-12-31 2012-07-18 沈阳药科大学 抗结核药物复方制剂的制备方法
WO2012139485A1 (zh) * 2011-04-12 2012-10-18 浙江海正药业股份有限公司 一种复方抗结核药口服固体制剂及其制备方法
CN105407874A (zh) * 2013-07-26 2016-03-16 赛诺菲 包含利福平、异烟肼、乙胺丁醇和吡嗪酰胺的抗结核病的组合物及其制备方法
CN106619702A (zh) * 2016-12-07 2017-05-10 郑州郑先医药科技有限公司 一种治疗肺结核的药物
CN108272766A (zh) * 2018-03-21 2018-07-13 江苏四环生物制药有限公司 一种甲钴胺分散迟释片及其制备方法
CN112472702A (zh) * 2020-12-14 2021-03-12 卓和药业集团有限公司 一种治疗肺结核的药物组合物及其制备方法
CN114053229A (zh) * 2022-01-17 2022-02-18 山东国邦药业有限公司 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300670B2 (en) * 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US20050084455A1 (en) * 2003-10-16 2005-04-21 Council Of Scientific & Industrial Research Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
RU2327457C1 (ru) * 2007-06-26 2008-06-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Лекарственное средство на основе рифабутина, препарат противомикробного действия, содержащий наночастицы, и способ его получения
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
KR101197277B1 (ko) * 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
AU2010213936B2 (en) * 2009-02-10 2014-07-31 Celgene Corporation Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management of tuberculosis
RU2012104843A (ru) * 2009-07-23 2013-08-27 Кадила Фармасьютикалз Лтд. Фармацевтическая композиция рифампицина
WO2011012987A1 (en) * 2009-07-31 2011-02-03 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of isoniazid
WO2011126352A2 (ru) * 2010-04-07 2011-10-13 Товарищество С Ограниченной Ответственностью "Фармацевтическая Компания "Ромат" Противотуберкулезный препарат на основе комплекса включения циклодекстрина с рифампицином и способ его получения
RU2423977C1 (ru) * 2010-04-20 2011-07-20 Открытое Акционерное Общество "Фармасинтез" Противотуберкулезное лекарственное средство на основе 4-тиоуреидоиминометилпиридиния перхлората, способ его получения и способ лечения
RU2435611C1 (ru) * 2010-05-17 2011-12-10 Общество с ограниченной ответственностью "ФАРМХИМ" (ООО "ФАРМХИМ") Способ получения полимерного комплекса
IT1400989B1 (it) * 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
TWI391134B (zh) * 2010-07-29 2013-04-01 Taiwan Biotech Co Ltd 製備抗結核病之組合的改良方法及由其製得之醫藥組合物
US8470365B2 (en) 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
EA016410B1 (ru) * 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
US9763885B2 (en) 2012-05-01 2017-09-19 Althera Laboratories Ltd. Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
WO2013166114A1 (en) * 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe
KR101301700B1 (ko) * 2012-11-14 2013-08-30 (주)비씨월드제약 용해도 및 안정성이 개선된 리팜피신을 포함하는 결핵 치료용 약학 조성물 및 이의 제조방법
WO2014147578A2 (en) * 2013-03-20 2014-09-25 Department Of Biotechnology Antibacterial compounds against drug resistant bacteria
JP2016539110A (ja) * 2013-07-26 2016-12-15 サノフイ イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法
RU2682178C2 (ru) * 2013-07-26 2019-03-15 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме таблетки с покрытием, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
WO2016105238A1 (ru) * 2014-12-22 2016-06-30 Анатолий Викторович ЗАЗУЛЯ Изготовление двухслойных таблеток объединяющих механизмы повышения терапевтической эффективности и коррекции побочных действий
US11717519B2 (en) * 2017-04-21 2023-08-08 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
WO2018226512A1 (en) * 2017-06-06 2018-12-13 Merck Sharp & Dohme Corp. Long-action implant for treatment of infectious diseases
EP3578167A1 (en) * 2018-06-04 2019-12-11 Universitat de Barcelona Suspension formulation for the treatment of tuberculosis
KR102304069B1 (ko) 2020-01-20 2021-09-23 인제대학교 산학협력단 항결핵제 치료 효과 증진용 조성물
CN115715808B (zh) * 2021-08-26 2025-01-24 丽珠医药集团股份有限公司 用于干混悬剂的干混悬颗粒及其制备方法和用途
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2025230986A1 (en) * 2024-04-29 2025-11-06 Anju Majeed Aqueous dispersion of molecules-process, formulation and method thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5817442B2 (ja) * 1977-04-25 1983-04-07 第一製薬株式会社 溶出の良いリフアンピシン固形製剤
GB2135879B (en) * 1983-03-07 1986-05-21 Ciba Geigy Ag Pharmaceutical preparations with uniform elution properties
JPH0498620A (ja) * 1990-08-15 1992-03-31 Nec Ibaraki Ltd 磁気記録媒体製造装置
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
EP0650728B1 (en) * 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
IT1289883B1 (it) * 1996-10-09 1998-10-19 Lupin Lab Ltd Composizione farmaceutica antitubercolare e procedimento per la sua produzione
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
BR9809310A (pt) * 1997-04-30 2000-07-04 Reckitt & Colmann Prod Ltd Composição lìquida aquosa derramável, composições farmacêuticas e processos para o tratamento da esofagite de refluxo, gastrite, dispepsia ou ulceração péptica, e para formar um revestimento protetor sobre o tecido da mucosa gastrintestinal, composição farmacêutica em forma de dosagem unitária sólida.
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
RU2153878C1 (ru) * 1999-04-27 2000-08-10 Пятигорская государственная фармацевтическая академия Способ получения лекарственных форм изониазида, обладающих пониженной гепатотоксичностью
ES2179729B1 (es) * 2000-03-23 2003-12-16 Dreiman Lab Farmaceuticos S A Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1857220B (zh) * 2006-04-04 2010-10-06 济南康泉医药科技有限公司 一种抗结核病药物缓释剂
CN102325526A (zh) * 2008-12-19 2012-01-18 Aai医药服务公司 延长释放的药物制剂
CN102325526B (zh) * 2008-12-19 2016-04-20 Aai医药服务公司 延长释放的药物制剂
US9555003B2 (en) 2011-04-12 2017-01-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Oral solid formulation of compound anti-tubercular drug and preparation method thereof
WO2012139485A1 (zh) * 2011-04-12 2012-10-18 浙江海正药业股份有限公司 一种复方抗结核药口服固体制剂及其制备方法
CN102228439A (zh) * 2011-06-21 2011-11-02 中国人民解放军第三○九医院 可注射利福霉素类抗生素凝胶微球及其制备方法
CN102228439B (zh) * 2011-06-21 2013-01-02 中国人民解放军第三0九医院 可注射利福霉素类抗生素凝胶微球及其制备方法
CN102552204A (zh) * 2011-12-30 2012-07-11 沈阳药科大学 复方抗结核包芯片及制备方法
CN102552204B (zh) * 2011-12-30 2014-04-02 沈阳药科大学 复方抗结核包芯片及制备方法
CN102579447A (zh) * 2011-12-31 2012-07-18 沈阳药科大学 抗结核药物复方制剂的制备方法
CN105407874A (zh) * 2013-07-26 2016-03-16 赛诺菲 包含利福平、异烟肼、乙胺丁醇和吡嗪酰胺的抗结核病的组合物及其制备方法
CN106619702A (zh) * 2016-12-07 2017-05-10 郑州郑先医药科技有限公司 一种治疗肺结核的药物
CN108272766A (zh) * 2018-03-21 2018-07-13 江苏四环生物制药有限公司 一种甲钴胺分散迟释片及其制备方法
CN108272766B (zh) * 2018-03-21 2020-07-07 江苏四环生物制药有限公司 一种甲钴胺分散迟释片及其制备方法
CN112472702A (zh) * 2020-12-14 2021-03-12 卓和药业集团有限公司 一种治疗肺结核的药物组合物及其制备方法
CN114053229A (zh) * 2022-01-17 2022-02-18 山东国邦药业有限公司 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法
CN114053229B (zh) * 2022-01-17 2022-04-22 山东国邦药业有限公司 一种盐酸沙拉沙星水溶性颗粒剂及其制备方法

Also Published As

Publication number Publication date
AU5666101A (en) 2002-02-18
AU778389C (en) 2006-12-14
AU778389B2 (en) 2004-12-02
NO20021599D0 (no) 2002-04-04
US20030072800A1 (en) 2003-04-17
ZA200202637B (en) 2003-08-20
KR20020061602A (ko) 2002-07-24
BG65848B1 (bg) 2010-03-31
KR100620404B1 (ko) 2006-09-13
JP2008056696A (ja) 2008-03-13
BG106606A (bg) 2002-12-29
UA74164C2 (uk) 2005-11-15
YU26102A (sh) 2004-12-31
CA2386725A1 (en) 2002-02-14
NO322503B1 (no) 2006-10-16
IL149030A0 (en) 2002-11-10
NZ518216A (en) 2004-11-26
JP4098620B2 (ja) 2008-06-11
HUP0203451A3 (en) 2004-05-28
PL355844A1 (en) 2004-05-31
JP2004505918A (ja) 2004-02-26
EP1307199A2 (en) 2003-05-07
WO2002011728A2 (en) 2002-02-14
RU2002115283A (ru) 2004-01-27
WO2002011728A3 (en) 2002-04-25
TR200200966T1 (tr) 2002-09-23
CZ20021319A3 (cs) 2002-08-14
BR0107147A (pt) 2002-06-18
MXPA02003596A (es) 2003-10-14
RU2240795C2 (ru) 2004-11-27
RU2240795C9 (ru) 2005-09-27
US7195769B2 (en) 2007-03-27
IL149030A (en) 2007-06-17
NO20021599L (no) 2002-06-10
HUP0203451A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
CN1388758A (zh) 抗结核病药物的新颖的药学组合物及其制备方法
CN1142792C (zh) 含质子泵抑制剂和促动力剂的口服药物剂型
CN100335043C (zh) 片剂化多重单元泡腾剂剂型口服药物组合物及其生产方法
CN1089583C (zh) 霉酚酸2－(4－吗啉代)乙酯高剂量口服悬浮剂
CN1222290C (zh) 新组合物及其用途
CN1098104C (zh) 新的口服药用剂型
CN1154490C (zh) 塞内昔布组合物
CN1182837C (zh) 包含吸收促进剂的可口服给药的即释和缓释盖仑制剂以及吸收促进剂的用途
CN1171587C (zh) 含有γ-氨基丁酸衍生物的固体组合物及其制备方法
CN101040855A (zh) 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
CN1217655A (zh) 改进释放的多单位剂量组合物
CN1334731A (zh) 新的药用制剂
CN1652752A (zh) 盐酸纳曲酮组合物
CN88101062A (zh) 持久释药的基质配方
CN1518442A (zh) 含有环孢菌素的药物组合物
CN1989963A (zh) 药用组合物
CN1596103A (zh) 用于治疗ii型糖尿病、包含二甲双胍和格列本脲的药物组合物
CN1575817A (zh) 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
CN1688304A (zh) 包括吲哚满酮化合物的制剂
CN1136852C (zh) 头孢克罗的制药用配方
CN1145488C (zh) 含硫氮�酮活性成分的缓释微粒
CN101032464A (zh) 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
CN1129429C (zh) 钾、钠和三羟甲基氨基甲烷噁丙嗪盐药物配方
CN1263450C (zh) 奥美拉唑及其衍生物的口腔崩解片及其制备工艺
CN1628648A (zh) 洛索洛芬钠缓释制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20030101